Literature DB >> 10560791

Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension.

A Bedir1, N Arik, B Adam, K Kilinç, T Gümüş, E Güner.   

Abstract

Studies in various ethnic groups have shown contradictory evidence on the association of the angiotensin converting enzyme (ACE) insertion/ deletion (I/D) polymorphism with essential hypertension. We conducted a case-control study in Samsun, Turkey, to examine the association between ACE genotype, ACE serum activity, and blood pressure. Serum ACE activity was measured and ACE I/D polymorphism performed in 165 hypertensive and 143 normotensive subjects. Genomic DNA was extracted from blood samples and amplified by polymerase chain reaction (PCR). PCR primers were flanking the polymorphic region in intron 16 of the ACE gene. The distribution of the DD, ID, and II ACE genotypes was 65, 77, and 23 in hypertensive patients and 42, 82, and 19 in normotensive subjects (P > .05). The estimated frequency of the insertion allele was 0.37 in hypertensive and 0.42 in normotensive subjects. Nevertheless, sensitivity analysis, based on positive family history and severity of hypertension, suggested that significant associations existed between more homogeneous groups of hypertensives and normotensives (P < .05). ACE genotype influenced ACE activity and the highest level was in DD genotype, being the lowest in II genotype. ACE serum levels were significantly higher in hypertensives as compared with normotensives (P < .01). A modest correlation was observed between blood pressure and ACE among hypertensive persons (r = 0.25, P < .05) and this did persist in multivariate analysis (P < .05 for systolic blood pressure and P < .005 for diastolic blood pressure). These data suggest that ACE DD genotype may have predisposing effects on severe hypertensives and cases with positive family history, and that ACE may be one of the independent factors on hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10560791     DOI: 10.1016/s0895-7061(99)00096-5

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey.

Authors:  Serif Yilmaz; Kadim Bayan; Yekta Tüzün; Sabri Batun; Abdullah Altintaş
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

2.  Renin-angiotensin system genes and exercise training-induced changes in sodium excretion in African American hypertensives.

Authors:  Jennifer M Jones; Jung-Jun Park; Jennifer Johnson; Dave Vizcaino; Brian Hand; Robert Ferrell; Matthew Weir; Thomas Dowling; Thomas Obisesan; Michael Brown
Journal:  Ethn Dis       Date:  2006       Impact factor: 1.847

3.  The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients.

Authors:  Christoph Röcken; Konrad Neumann; Stacy Carl-McGrath; Hermann Lage; Matthias P A Ebert; Jutta Dierkes; Christoph A Jacobi; Sinan Kalmuk; Peter Neuhaus; Ulf Neumann
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

4.  Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta-analysis.

Authors:  Chao Han; Xi-Kun Han; Fang-Chao Liu; Jian-Feng Huang
Journal:  Chronic Dis Transl Med       Date:  2017-09-18

5.  The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019.

Authors:  Zhe Zhu; Ting Cai; Lingyan Fan; Kehong Lou; Xin Hua; Zuoan Huang; Guosheng Gao
Journal:  BMC Infect Dis       Date:  2020-11-25       Impact factor: 3.090

6.  Association between angiotensin converting enzyme gene polymorphism and essential hypertension: A systematic review and meta-analysis.

Authors:  Mingyu Liu; Jian Yi; Wenwen Tang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021 Jan-Dec       Impact factor: 1.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.